公开(公告)号：US20230075092A1

公开(公告)日：2023-03-09

申请号：US17792403

申请日：2021-01-12

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE LAVAL ,  SIGNIA THERAPEUTICS ,  ECOLE NORMALE SUPERIEURE DE LYON

发明人： Olivier TERRIER ,  Manuel ROSA-CALATRAVA ,  Guy BOIVIN ,  Mario-Andres PIZZORNO ,  Blandine PADEY

IPC分类号： A61K31/554 ,  A61K9/00 ,  A61K31/5383 ,  A61K45/06 ,  A61P31/16

摘要： The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

公开(公告)号：US20230210866A1

公开(公告)日：2023-07-06

申请号：US17905562

申请日：2021-03-10

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSERM (Institut National de la Sante et de la Recherche Medicale) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  ECOLE NORMALE SUPERIEURE DE LYON ,  SIGNIA THERAPEUTICS

发明人： Manuel ROSA-CALATRAVA ,  Olivier TERRIER ,  Mario Andres PIZZORNO ,  Aurelien TRAVERSIER ,  Blandine PADEY ,  Thomas JULIEN

IPC分类号： A61K31/554 ,  A61P31/14 ,  A61K31/7076 ,  A61K45/06

CPC分类号： A61K31/554 ,  A61K31/7076 ,  A61K45/06 ,  A61P31/14

摘要： The present invention relates to a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical carrier for its therapeutic use in the prevention and/or treatment of a viral infection caused by the SARS-CoV-2 virus, referred to as COVID-19 disease.